Kane Biotech (KNE) investor relations material

Market need and healthcare crisis

• Chronic wounds and biofilms cause over 130,000 amputations annually among diabetic patients in the US, with a significant economic burden and high treatment costs exceeding $100,000 per burn case.

• 10.5 million Medicare beneficiaries suffer from chronic wounds, and 700,000 burn-related insurance claims are filed each year.

• Biofilms are present in 80% of chronic wounds and 70% of burn wounds, making bacteria up to 1,000 times more resistant to antibiotics.

Technology and clinical validation

• revyve® technology disrupts biofilms, kills bacteria, and supports healing with a patented coactiv+ system and sustained antimicrobial action for up to 7 days.

• Clinical case studies show significant healing and pain reduction in chronic wound patients, including diabetic foot and venous leg ulcers.

• Real-world case series across 9 centers in the US and Canada report high rates of healing transition and positive clinician feedback.

• Laboratory data confirm >99.99% kill rates against antibiotic-resistant pathogens, including MRSA, with no regrowth over 7 days.

Product portfolio and competitive advantage

• Two FDA-cleared formats: antimicrobial wound gel (tube) and non-aerosol spray, both Health Canada approved and Medicare reimbursable.

• Products offer biofilm disruption, 7-day antimicrobial duration, painless application, and accessible pricing compared to advanced biologics.

• revyve® addresses gaps left by current standards, combining biofilm disruption, sustained antimicrobial action, ease of use, and reimbursement.